ArticleThe oncologist2023

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.

Junning Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.